Unlearn is the only company creating Twintelligent RCTs™, which combine AI, Digital Twins, and novel statistical methods to enable smaller, more efficient trials. Twintelligent RCTs™ incorporate prognostic information from Digital Twins into randomized controlled trials to enable smaller control groups and generate evidence suitable for supporting regulatory decisions. Unlearn’s technology has been published in conference abstracts and scientific journals, including Scientific Reports – Nature and The International Journal of Biostatistics. Unlearn is partnering with the world’s leading pharma companies and continues to have discussions with regulators, including the FDA and EMA. The company is backed by 8VC, Alumni Ventures Group, DCVC, DCVC Bio, Eisai, Epic Ventures, and Mubadala Capital Ventures. Unlearn.AI was awarded “Predictive Analytics Solution of the Year” in the 2021 BioTech Breakthrough Awards Program. CB Insights named Unlearn to the 2021 AI 100 List of Most Innovative Artificial Intelligence Startups and to the 2020 Digital Health 150 List of Most Innovative Digital Health Startups.